Biosimilars applications under review by EMA

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Biosimilars applications under review by EMA – January 2022

Biosimilars/General | Posted 21/01/2022 0 Post your comment

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ‘similarity’ to the originator or reference drug.

All medicines for human and animal use derived from biotechnology and other high-tech processes (including biosimilars) must be approved via the centralized EMA procedure. EMA has both general and product specific guidelines giving information on the requirements for biosimilar applications submitted to EMA [1].

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 4 January 2022, the agency is reviewing 13 biosimilar applications. One application is for haemophilia treatment eptacog alfa and one is for diabetes treatment insulin human (rDNA). There are currently no biosimilars for these products approved in Europe [2].

The other applications are two for anticancer treatment bevacizumab, one for diabetes treatment insulin aspart, three for neutropenia (a lack of white blood cells) treatment in cancer patients pegfilgrastim, three for osteoporosis treatment teriparatide and two for breast and gastric-cancer treatment trastuzumab, for which there are already biosimilars available on the European market [2], see Table 1.

Table 1: Biosimilars under review by EMA*

Common name	Therapeutic area	Number of applications	EMA-approved originator(s)	Originator company(ies)
Bevacizumab	Anti‑neoplastic medicines (anticancer)	2	Avastin	Roche
Eptacog alfa	Anti‑haemorrhagic (haemophilia)	1	NovoSeven	Novo Nordisk
Insulin aspart	Diabetes	1	NovoLog	Novo Nordisk
Insulin human (rDNA)	Diabetes	1	Actrapid/ Humulin	Novo Nordisk/ Eli Lilly
Pegfilgrastim	Immunostimulant (neutropenia)	3	Neulasta	Amgen
Teriparatide	Calcium homeostasis (osteoporosis)	3	Forsteo	Eli Lilly
Trastuzumab	Antineoplastic medicines (anticancer)	2	Herceptin	Roche
Total		13

*Data collected on 18 January 2022.
rDNA: recombinant deoxyribonucleic acid.
Source: EMA.

The ranibizumab biosimilar Byooviz was approved in Europe in August 2021 [3].

Then, in October 2021, the EMA’s CHMP recommended approval of the adalimumab biosimilars Hukyndra and Libmyris [4].

Related articles

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. EC and FDA approval for first ranibizumab biosimilar Byooviz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from: www.gabionline.net/biosimilars/news/EC-and-FDA-approval-for-first-ranibizumab-biosimilar-Byooviz
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of two adalimumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from: www.gabionline.net/biosimilars/news/EMA-recommends-approval-of-two-adalimumab-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: EMA